免疫性血小板减少症
肠道菌群
基因组
拟杆菌
微生物群
免疫系统
小桶
肠道微生物群
生物标志物
失调
医学
支持向量机
免疫学
机器学习
内科学
血小板
生物信息学
生物
计算机科学
转录组
细菌
生物化学
遗传学
基因表达
基因
作者
Fengqi Liu,Zhuo‐Yu An,Lijuan Cui,M. Xiao,Yejun Wu,Wei Li,Bang‐Shuo Zhang,Yu Li,Jia Feng,Zhuo‐Gang Liu,Ru Feng,Zhong‐Xing Jiang,Rui‐Bin Huang,Hongmei Jing,Jinhai Ren,Xiaoyu Zhu,Yunfeng Cheng,Yuhua Li,Hebing Zhou,Da Gao
标识
DOI:10.1002/advs.202410417
摘要
Corticosteroids (CSs) are the initial therapy for immune thrombocytopenia (ITP); however, their efficacy is not adequately predicted. As a novel biomarker, the composition of the gut microbiota is non-invasively tested and altered in patients with ITP. This study aims to develop a predictive model that leverages gut microbiome data to predict the CS response in patients with ITP within the initial four weeks of treatment. Metagenomic sequencing is performed on fecal samples from 212 patients with ITP, 152 of whom underwent CS treatment and follow-up. Predictive models are trained using six machine-learning algorithms, integrating clinical indices and gut microbiome data. The support vector machine (SVM) algorithm-based model has the highest accuracy (AUC = 0.80). This model utilized a comprehensive feature set that combined clinical data (including sex, age, duration, platelet count, and bleeding scales) with selected microbial species (including Bacteroides ovatus, Bacteroides xylanisolvens, and Parabacteroides gordonii), alpha diversities, KEGG pathways, and microbial modules. This study will provide new ideas for the prediction of clinical CS efficacy, enabling informed decision-making regarding the initiation of CS or personalized treatment in patients with ITP.
科研通智能强力驱动
Strongly Powered by AbleSci AI